Ipratropium/Salbutamol Orion (Ipratropium Bromide, Salbutamol)

Ipratropium bromide is a muscarinic antagonist that blocks acetylcholine receptors on airway smooth muscle, preventing the cholinergic reflex that causes bronchoconstriction. By inhibiting this pathway, it reduces airway narrowing and improves airflow, especially when used together with a β2‑agonist.

The specific dose and frequency of Ipratropium/Salbutamol Orion are determined by the prescribing healthcare professional based on the patient’s condition, severity of symptoms, and response to therapy. Patients should follow the prescriber’s instructions and the device’s dosing guidelines.

Safety data in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

The combination delivers both anticholinergic and β2‑agonist actions in a single inhalation, offering faster and more complete bronchodilation than either agent alone. This can reduce the need for multiple inhalers, improve adherence, and provide synergistic relief during acute bronchospasm.

Store the inhalation solution at room temperature below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use to maintain product stability.

The product is delivered via a metered‑dose inhaler or nebulizer, depending on the formulation supplied. Patients should inhale the prescribed number of puffs or nebulized doses as instructed by their healthcare provider, ensuring proper technique to maximize drug delivery to the lungs.

Serious risks include paradoxical bronchospasm, which can worsen breathing, and rare allergic reactions such as angioedema or anaphylaxis. Cardiovascular effects like tachycardia, arrhythmias, and significant hypokalemia may also occur, especially in patients with underlying heart disease or those taking interacting medications.

Patients with a known hypersensitivity to ipratropium, salbutamol, or any excipients in the formulation should avoid the product. It is also contraindicated in individuals with severe narrow‑angle glaucoma or urinary retention caused by anticholinergic effects, unless specifically advised by a physician.